-transparent.png){kind=logo}
Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database. 2010
Eva Poveda, and
Lourdes Anta, and
José Luis Blanco, and
Maria Jesús Pérez-Elías, and
Federico García, and
Manuel Leal, and
Esteban Ribera, and
Félix Gutiérrez, and
Vincent Soriano, and
Carmen de Mendoza, and
Hospital Carlos III, Madrid, Spain.
The prevalence of etravirine resistance mutations was examined in genotypes derived from 1343 HIV-infected patients failing nevirapine or efavirenz in the resistance database of the Spanish AIDS Research Network (ResRIS). Overall, etravirine-resistant genotypes were recognized in 18.7% of patients, with no significant differences between failures under nevirapine or efavirenz. Thus, more than 80% patients with prior failure to nonnucleoside reverse transcriptase inhibitors could potentially benefit from etravirine rescue therapy.
Related Publications
Eva Poveda, and
Lourdes Anta, and
José Luis Blanco, and
Maria Jesús Pérez-Elías, and
Federico García, and
Manuel Leal, and
Esteban Ribera, and
Félix Gutiérrez, and
Vincent Soriano, and
Carmen de Mendoza, and
August 2018,
AIDS research and human retroviruses,
Eva Poveda, and
Lourdes Anta, and
José Luis Blanco, and
Maria Jesús Pérez-Elías, and
Federico García, and
Manuel Leal, and
Esteban Ribera, and
Félix Gutiérrez, and
Vincent Soriano, and
Carmen de Mendoza, and
January 2014,
AIDS (London, England),
Eva Poveda, and
Lourdes Anta, and
José Luis Blanco, and
Maria Jesús Pérez-Elías, and
Federico García, and
Manuel Leal, and
Esteban Ribera, and
Félix Gutiérrez, and
Vincent Soriano, and
Carmen de Mendoza, and
January 2011,
PloS one,
Eva Poveda, and
Lourdes Anta, and
José Luis Blanco, and
Maria Jesús Pérez-Elías, and
Federico García, and
Manuel Leal, and
Esteban Ribera, and
Félix Gutiérrez, and
Vincent Soriano, and
Carmen de Mendoza, and
February 2015,
The Journal of antimicrobial chemotherapy,
Eva Poveda, and
Lourdes Anta, and
José Luis Blanco, and
Maria Jesús Pérez-Elías, and
Federico García, and
Manuel Leal, and
Esteban Ribera, and
Félix Gutiérrez, and
Vincent Soriano, and
Carmen de Mendoza, and
November 2008,
The Journal of antimicrobial chemotherapy,
Eva Poveda, and
Lourdes Anta, and
José Luis Blanco, and
Maria Jesús Pérez-Elías, and
Federico García, and
Manuel Leal, and
Esteban Ribera, and
Félix Gutiérrez, and
Vincent Soriano, and
Carmen de Mendoza, and
June 2010,
AIDS research and human retroviruses,
Eva Poveda, and
Lourdes Anta, and
José Luis Blanco, and
Maria Jesús Pérez-Elías, and
Federico García, and
Manuel Leal, and
Esteban Ribera, and
Félix Gutiérrez, and
Vincent Soriano, and
Carmen de Mendoza, and
January 2019,
Infectious diseases (London, England),
Eva Poveda, and
Lourdes Anta, and
José Luis Blanco, and
Maria Jesús Pérez-Elías, and
Federico García, and
Manuel Leal, and
Esteban Ribera, and
Félix Gutiérrez, and
Vincent Soriano, and
Carmen de Mendoza, and
May 2004,
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Eva Poveda, and
Lourdes Anta, and
José Luis Blanco, and
Maria Jesús Pérez-Elías, and
Federico García, and
Manuel Leal, and
Esteban Ribera, and
Félix Gutiérrez, and
Vincent Soriano, and
Carmen de Mendoza, and
September 2014,
AIDS (London, England),
Eva Poveda, and
Lourdes Anta, and
José Luis Blanco, and
Maria Jesús Pérez-Elías, and
Federico García, and
Manuel Leal, and
Esteban Ribera, and
Félix Gutiérrez, and
Vincent Soriano, and
Carmen de Mendoza, and
June 2015,
Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases,
